Balyasny Asset Management
XFOR icon

Balyasny Asset Management’s X4 Pharmaceuticals XFOR Stock Holding History

Balyasny Asset Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-64,505
Closed -$258K – 3612
2025
Q4 		$258K Buy
+64,505
New +$234K ﹤0.01% 2796

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Balyasny Asset Management's XFOR Position: Q1 2026 in Review

Balyasny Asset Management sold out of X4 Pharmaceuticals (XFOR) in Q1 2026, closing a stake of 64,505 shares — an estimated $258K sold.

Balyasny Asset Management first reported a position in XFOR in Q4 2025 and held it in 1 quarter. The position peaked at $258K in Q4 2025. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Balyasny Asset Management reported no remaining X4 Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 64,505 X4 Pharmaceuticals shares in Q1 2026, an estimated $258K.
  • Balyasny Asset Management first reported a position in X4 Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Balyasny Asset Management's X4 Pharmaceuticals position peaked at $258K in Q4 2025.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.